Bull Case

Positive clinical or partnering catalysts lift demand and non-dilutive funding, allowing INMB to outpace small-cap immunotherapy peers that remain dependent on repeated equity raises.

Improved trial execution and cleaner data readouts reduce development risk, which can re-rate revenue expectations faster than peers with broader pipelines but weaker near-term catalysts.

Tighter operating discipline and lower cash burn extend runway, improving financing terms versus peers with similar stage assets but weaker balance-sheet flexibility.

A favorable regulatory or partnership outcome expands commercialization optionality, creating a sharper path to monetization than peers still stuck in pre-proof-of-concept stages.

Base Case

Clinical progress remains incremental and funding stays available but dilutive, leaving INMB broadly in line with early-stage biotech peers that trade on milestone timing.

Operating losses persist while management prioritizes pipeline advancement, so valuation remains driven by event risk rather than durable revenue generation.

Cash preservation improves modestly, but limited scale keeps financing pressure above larger peers with multiple programs and stronger internal funding capacity.

Bear Case

Trial setbacks or weak efficacy data reduce probability-adjusted pipeline value, causing INMB to underperform peers with more diversified clinical assets.

Higher burn and limited access to capital force repeated dilution or restructuring, a worse outcome than better-capitalized peers that can fund longer development cycles.

Regulatory delays or enrollment slippage push commercialization further out, compressing valuation as investors favor peers with clearer near-term catalysts and stronger balance sheets.

Overall Score

INMB’s forward path is most likely to remain event-driven and financing-sensitive, with upside tied to clinical catalysts but constrained by persistent dilution risk versus peers.